Media & Resources

Filter by

Press Releases

IAVI Announces Clinical Trial of Next-Generation HIV Vaccine Candidate Designed to Induce Antibodies to Block HIV Infection

October 8, 2018

Phase I trial to evaluate safety and immunogenicity of vaccine candidate engineered to elicit targeted immune response against HIV.

Scientific Publications

Characterization of the membrane bound form of the chimeric B C recombinant HIV 1 Env LT5 J4b12C

Press Releases

IAVI Acquires Aeras TB Vaccine Clinical Programs and Assets

October 1, 2018

Data from two Phase II clinical trials conducted by Aeras and partners indicate promise for future of TB vaccine development.

Features

Scientific Advances Spur New Hope for Defeating TB

October 1, 2018

After decades of research, renewed promise emerges for developing vaccines against the world’s deadliest infectious disease.

Scientific Publications

Bacterially expressed HIV 1 gp120 outer domain fragment immunogens with improved stability and affinity for CD4 binding site neutralizing antibodies

In The News

The number of new HIV cases in India is falling but not fast enough and there’s a risk of resurgence

September 27, 2018

Features

HIVR4P 2018

September 19, 2018

IAVI and our partners head to Madrid on Oct. 21 to 25 for the 2018 HIV Research for Prevention conference.

Scientific Publications

Antisense Derived HIV 1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection

1…82 838485 86…218 of 218

Media & Resources

Filter by

Type

Health area

Location

Topic

Year

Journal

Publication

Fact sheet & publication type

IAVI Announces Clinical Trial of Next-Generation HIV Vaccine Candidate Designed to Induce Antibodies to Block HIV Infection

Characterization of the membrane bound form of the chimeric B C recombinant HIV 1 Env LT5 J4b12C

IAVI Acquires Aeras TB Vaccine Clinical Programs and Assets

Scientific Advances Spur New Hope for Defeating TB

Bacterially expressed HIV 1 gp120 outer domain fragment immunogens with improved stability and affinity for CD4 binding site neutralizing antibodies

The number of new HIV cases in India is falling but not fast enough and there’s a risk of resurgence

HIVR4P 2018

Antisense Derived HIV 1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection

Media & Resources

Filter by

Type

Health area

Location

Topic

Year

Journal

Publication

Fact sheet & publication type

IAVI Announces Clinical Trial of Next-Generation HIV Vaccine Candidate Designed to Induce Antibodies to Block HIV Infection

Characterization of the membrane bound form of the chimeric B C recombinant HIV 1 Env LT5 J4b12C

IAVI Acquires Aeras TB Vaccine Clinical Programs and Assets

Scientific Advances Spur New Hope for Defeating TB

Bacterially expressed HIV 1 gp120 outer domain fragment immunogens with improved stability and affinity for CD4 binding site neutralizing antibodies

The number of new HIV cases in India is falling but not fast enough and there’s a risk of resurgence

HIVR4P 2018

Antisense Derived HIV 1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection

Subscription Type